Immune Checkpoint Inhibitor-Induced Hemorrhagic Gastritis

Authors

Karthik Mathialagan, Department of Medicine, Yale-New Haven Health-Bridgeport Hospital, Bridgeport, CT.Follow
Cheng-Hung Tai, Section of Gastroenterology, Department of Medicine, Yale-New Haven Health-Bridgeport Hospital, Bridgeport, CT.
Samdish Sethi, Department of Medicine, Yale-New Haven Health-Bridgeport Hospital, Bridgeport, CT.Follow
Sumi Thomas, Department of Pathology, Yale University School of Medicine, New Haven, CT.
Caroline Loeser, Section of Gastroenterology, Department of Medicine, Yale-New Haven Health-Bridgeport Hospital, Bridgeport, CT.

Document Type

Article

Publication Title

ACG case reports journal

Abstract

Immune checkpoint inhibitors (ICIs) have been increasingly used in the treatment of several malignancies and may target cytotoxic T-lymphocyte-associated antigen-4, programmed cell death-1, and programmed cell death ligand 1, which work on maintaining peripheral immune tolerance. ICIs inhibit these ligands causing an immune-enhancing effect, leading to a wide spectrum of complications from mild mucositis to life-threatening pneumonitis or hepatitis. These complications are collectively called immune-related adverse events. Their prevalence has increased with a rise in ICI use, with rare manifestations being reported in popular literature. We present a case of hemorrhagic gastritis due to the anti-programmed cell death-1 antibody, pembrolizumab.

First Page

e01128

DOI

10.14309/crj.0000000000001128

Publication Date

8-1-2023

Recommended Citation

Mathialagan, Karthik; Tai, Cheng-Hung; Sethi, Samdish; Thomas, Sumi; and Loeser, Caroline, "Immune Checkpoint Inhibitor-Induced Hemorrhagic Gastritis" (2023). Internal Medicine. 73.
https://scholar.bridgeporthospital.org/internal_medicine/73

Identifier

37583508 (pubmed); PMC10424893 (pmc); 10.14309/crj.0000000000001128 (doi); ACGCR-23-0467 (pii)